NIH | National Cancer Institute | NCI Wiki  

Date

Attendees

Committee MemberPresentAbsent
Kuffel, Gina (NIH/NCI) [C]
X

Musk, Philip (NIH/NCI) [C]

X

Unknown User (wak11@duke.edu.commons)

X
Kim, Erika (NIH/NCI) [E]

X
Gregory TawaX
William HendriksX
Matthew Breen
X
Roel VerhaakX



Goals

  • Review, discuss, and prioritize ICDC study submission proposals

Outstanding Action items

  • Matthew & Warren to write an email request to Toby pertaining to formalization of a business plan for ICDC.
  • Musk, Philip (NIH/NCI) [C] to brush up on Nanostring documentation.
  • Kuffel, Gina (NIH/NCI) [C] to organize and circulate other Modiano publications that have genomic data available

Agenda

Discussion ItemWhoNotes
PRECINCT Data Request Submission: Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases

All

Review of other Modiano publications: Other Modiano Publication Considerations.xlsx

Kuffel, Gina (NIH/NCI) [C]

Study Updates

Musk, Philip (NIH/NCI) [C]

  • TCL01
    • Study identifier changed to TCL01 (Tumor Cell Line)
    • Required substantial curation on our end
    • Changes are being reviewed by the Duval group
  • PRECINCT
    • Program now available on lower tier (dev environment)
    • Study record is in place

Minutes (Not Verbatim)

Warren - Take this submission request to a vote.

WK - This is the first NanoString data submission. That is an advantage of this program as well.

PM - Correct. Even if this study is thin on data as of release, we are set up for handling similar datasets coming out of the other PRECINCT trials. This will involve new data types and data model changes.

Voting for PRECINCT submission:  Warren, Will, and Greg recommend to bring in the study.

PM - Are there are study level files for the OSA01 study? 

WH - Heather can provide those.

Action items